| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ADEPTUS HEALTH Aktie jetzt für 0€ handeln |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 15,790 | +0,45 % | Eckert & Ziegler - Kurzbericht zur Aktienentwicklung | ||
| MEDTRONIC | 85,12 | -0,83 % | Medtronic Benefits Are Built for Every Chapter | Employees feel confident in their future, cared for in the present, and supported through life's biggest moments. NORTHAMPTON, MA / ACCESS Newswire / January 5, 2026 / As a global leader in healthcare... ► Artikel lesen | |
| FAMICORD | 5,950 | 0,00 % | EQS-News: FamiCord AG beschleunigt profitables Wachstum im dritten Quartal 2025 und stärkt Qualität und Visibilität der Umsatzentwicklung | EQS-News: FamiCord AG
/ Schlagwort(e): 9-Monatszahlen
FamiCord AG beschleunigt profitables Wachstum im dritten Quartal 2025 und stärkt Qualität und Visibilität der Umsatzentwicklung... ► Artikel lesen | |
| PLUS THERAPEUTICS | 0,605 | 0,00 % | Plus Therapeutics Inc.: Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ in Leptomeningeal Metastases | HOUSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals... ► Artikel lesen | |
| DAVITA | 98,70 | +0,55 % | Caring for Caregivers: DaVita's Investment in Nursing Education and Growth | NORTHAMPTON, MA / ACCESS Newswire / January 2, 2026 / As chronic disease rates climb[1], the U.S. faces a critical shortage of nurses - creating an urgent need for innovative solutions in healthcare... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,585 | +3,91 % | Atossa Therapeutics Inc: Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer | SEATTLE, Jan. 6, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing innovative medicines for unmet... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 46,310 | +0,46 % | DEUTSCHE BANK RESEARCH stuft Siemens Healthineers auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Siemens Healthineers auf "Hold" mit einem Kursziel von 46 Euro belassen. Er rechne damit, dass der Start in das neue Geschäftsjahr... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 39,180 | -2,59 % | EILMELDUNG: Fresenius Medical Care-Aktie im freien Fall - Anleger fliehen aus dem Wert! | ||
| FRESENIUS | 48,970 | +1,09 % | Amneal Pharma, MAbxience: FDA Approves Denosumab Biosimilars Referencing Amgen's Prolia And XGEVA | THOUSAND OAKS (dpa-AFX) - Amneal Pharmaceuticals, Inc. (AMRX) announced late Monday that the U.S. Food and Drug Administration has approved the Biologics Licensing Applications or BLAs for Boncresa... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 39,510 | -2,85 % | S&P Dow Jones Indices: BrightSpring Health Services Set to Join S&P SmallCap 600 | NEW YORK, Oct. 14, 2025 /PRNewswire/ -- BrightSpring Health Services Inc. (NASD: BTSG) will replace Veritex Holdings Inc. (NASD: VBTX) in the S&P SmallCap 600 effective... ► Artikel lesen | |
| PROGYNY | 26,800 | +0,49 % | Progyny, Inc. Announces Third Quarter 2025 Results | Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 24,200 | -0,94 % | Citizens reiterates Market Outperform rating on Privia Health stock | ||
| PROCEPT BIOROBOTICS | 33,920 | -2,30 % | PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance | SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| GENEDX | 136,55 | +0,55 % | GeneDx to launch whole genome sequencing test for fetal anomalies | ||
| HEARTFLOW | 32,580 | +4,42 % | Heartflow, Inc.: Heartflow FFRCT Analysis Delivers Prognostic Power and Significant Cost Savings in New Analyses of Over 90,000 Patients with Coronary Artery Disease | Lesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England's National Health ServiceMOUNTAIN... ► Artikel lesen |